# Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

> **NCT03368170** · PHASE2 · COMPLETED · sponsor: **Integrative Research Laboratories AB** · enrollment: 75 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Mesdopetam (IRL790)

## Key facts

- **NCT ID:** NCT03368170
- **Lead sponsor:** Integrative Research Laboratories AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-12
- **Primary completion:** 2019-06-12
- **Final completion:** 2019-06-12
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2022-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03368170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03368170, "Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03368170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*